Ulcerban en es it fr

Ulcerban Brand names, Ulcerban Analogs

Ulcerban Brand Names Mixture

  • No information avaliable

Ulcerban Chemical_Formula

C13H10N2O4

Ulcerban RX_link

http://www.rxlist.com/cgi/generic2/thalidom.htm

Ulcerban fda sheet

Ulcerban FDA

Ulcerban msds (material safety sheet)

Ulcerban MSDS

Ulcerban Synthesis Reference

No information avaliable

Ulcerban Molecular Weight

258.23 g/mol

Ulcerban Melting Point

270 oC

Ulcerban H2O Solubility

545 mg/L

Ulcerban State

Solid

Ulcerban LogP

-0.146

Ulcerban Dosage Forms

Tablets for oral administration (50 mg); Capsules for oral administration (50 mg, 100 mg and 200 mg)

Ulcerban Indication

For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Ulcerban Pharmacology

Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.

Ulcerban Absorption

The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.

Ulcerban side effects and Toxicity

The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.

Ulcerban Patient Information

Ulcerban Organisms Affected

Humans and other mammals